Evidence map›Paper›PMID 40872482›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Novel Strategies for the Formulation of Poorly Water-Soluble Drug Substances by Different Physical Modification Strategies with a Focus on Peroral Applications.

Julian Quodbach, Eduard Preis, Frank Karkossa, Judith Winck, Jan Henrik Finke, Denise Steiner

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julian QuodbachDivision of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3484 CG Utrecht, The Netherlands.ORCID 0000-0003-2471-4502
Eduard PreisDepartment of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Philipps-Universität Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany.ORCID 0000-0003-2112-8436
Frank KarkossaDepartment of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Felix-Hausdorff-Straße 3, 17489 Greifswald, Germany.ORCID 0000-0002-9164-5407
Judith WinckLaboratory of Solids Process Engineering, TU Dortmund University, Emil-Figge-Str. 68, 44227 Dortmund, Germany.ORCID 0000-0001-8364-7958
Jan Henrik FinkeInstitute for Particle Technology, Technische Universität Braunschweig, Volkmaroder Str. 4, 38104 Braunschweig, Germany.ORCID 0000-0001-6936-9795
Denise SteinerInstitute of Pharmaceutical Technology and Biopharmaceutics, University of Muenster, Corrensstraße 48, 48149 Muenster, Germany.ORCID 0000-0001-6450-9234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of newly developed substances with poor water solubility continually increases. Therefore, specialized formulation strategies are required to overcome the low bioavailability often associated with this property. This review provides an overview of novel physical modification strategies discussed in the literature over the past decades and focuses on oral dosage forms. A distinction is made between 'brick-dust' molecules, which are characterized by high melting points due to the solid-state properties of the substances, and 'grease-ball' molecules with high lipophilicity. In general, the discussed strategies are divided into the following three main categories: drug nanoparticles, solid dispersions, and lipid-based formulations.

Indexed as

bioavailabilitydrug carrier systemsdrug delivery systemsdrug nanoparticleslipid-based formulationsphysical modificationsolid dispersions

Identifiers

PMID40872482
PMCPMC12388907

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.